Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology

Zhang, Zhouwei; Weaver, Donald L.; Olsen, Daniel; deKay, James; Peng, Zhihua; Ashikaga, Takamaru; Evans, Mark

doi:10.1136/jclinpath-2015-203275

Cited by 70 publications

(65 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MALAT1, a well-known lncRNA and possible oncogene (16), is upregulated in malignancies of multiple organs (10). RNA ISH enables direct visualization of lncRNAs, and strong MALAT1 hybridization signals were previous reported in breast malignancies (17). In this study, we examined the expression level of MALAT1 in normal thyroid tissue as well as benign and malignant neoplasms using ISH and real-time PCR validation.…”

Section: Discussionmentioning

confidence: 64%

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR

et al. 2016

View full text Add to dashboard Cite

Long noncoding RNAs (lncRNAs) are important for transcription and for epigenetic or posttranscriptional regulation of gene expression, and may contribute to carcinogenesis. MALAT1 (Metastasis Associated Lung Adenocarcinoma Transcript 1), a lncRNA involved in the regulation of the cell cycle, cell proliferation and cell migration, is known to be deregulated in multiple cancers. Here we analyzed the expression of MALAT1 on 195 cases of benign and malignant thyroid neoplasms by using tissue microarrays for RNA in-situ hybridization (ISH) and real-time PCR. MALAT1 is highly expressed in normal thyroid tissues (NT) and thyroid tumors, with increased expression during progression from NT to papillary thyroid carcinomas (PTCs), but is downregulated in poorly differentiated thyroid cancers (PDCs) and anaplastic thyroid cancers (ATCs) compared to NT. Induction of epithelial to mesenchymal transition (EMT) by TGF beta in a PTC cell line (TPC1) led to increased MALAT1 expression, supporting a role for MALAT1 in EMT in thyroid tumors. This is the first ISH study of MALAT1 expression in thyroid tissues. It also provides the first piece of evidence suggesting MALAT1 downregulation in certain thyroid malignancies. Our findings support the notion that ATCs may be molecularly distinct from low grade thyroid malignancies, and suggest that MALAT1 may function both as an oncogene and as a tumor suppressor in different types of thyroid tumors.

show abstract

Section: Discussionmentioning

confidence: 64%

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR

et al. 2016

View full text Add to dashboard Cite

show abstract

“…ZFAS1 was originally identified a regulator of alveolar development and epithelial cell differentiation in the mammary gland [16], subsequently studies showed ZFAS1 was aberrantly down-regulated in breast cancer tissues and cells [16, 18, 19]. Recent studies have demonstrated that ZFAS1 was overexpressed in various cancer tissues and cell lines, and promoted the cancer progression through affecting the phenotypes of cancer cells and molecular pathways.…”

Section: Discovery Of Zfas1mentioning

confidence: 99%

“…Askarian-Amiri et al [16] reported ZFAS1 was overexpressed in the mammary gland and down-regulated in breast tumors. Zhang et al [19] found ZFAS1 was negative or weakly expressed in breast cancer. Lee et al [21] found ZFAS1 was downexpression in HER2-positive breast cancer cells.…”

Section: Zfas1 In Various Cancersmentioning

confidence: 99%

“…ZNFX1 antisense RNA 1 ( ZFAS1 ), an lncRNA originally identified a regulator of mammary development [16]. Subsequent studies also demonstrated that ZFAS1 expression is upregulated in many human malignancies, including glioma, lung, colon, liver, ovary and gastric cancers [17], but downregulated in breast cancer [16, 18, 19]. The present review summarizes the current studies of regulation mechanisms and functions of ZFAS1 in the initiation and progression of human cancers (Tables 1, 2).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

ZFAS1: a novel tumor-related long non-coding RNA

Dong

Zhao

et al. 2018

Cancer Cell Int

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNA) are classified as a kind of RNA, which are longer than 200 nucleotides in length and cannot be translated into proteins. Multiple studies have demonstrated that lncRNAs are involved in various cellular processes, including proliferation, differentiation, cell death, and metastasis. In addition, aberrant expression of lncRNAs has been discovered in human tumors, where they function as either oncogenes or tumor suppressor genes. Among numerous lncRNAs, we focus on ZNFX1 antisense RNA 1 (ZFAS1), a well-known lncRNA that is aberrant overexpression in various tumors, including melanoma, esophageal squamous cell carcinoma, non-small cell lung cancer, gastric cancer, colon cancer, and Hepatocellular carcinoma, in which it functions as oncogene. In contrast, ZFAS1 is downregulated in breast cancer, which may function as tumor suppressor gene. In this review, we provide an overview of current evidence concerning the role and potential clinical utilities of ZFAS1 in human cancers.

show abstract

“…However, there were opposite findings that elevated lncRNA ZFAS1 occurred in gastric cancer, hepatocellular carcinoma and glioma. The function of lncRNA ZFAS1 in cancer cells might be cell type-dependent [12][13][14][15][16][17][18][19][20]. Therefore, we need a systematical and comprehensive meta-analysis to explore whether overexpression of ZFAS1 in tumor are related to worse outcome.…”

Section: Oncotarget 2 Wwwimpactjournalscom/oncotargetmentioning

confidence: 99%

Prognostic and clinicopathological role of long non-coding RNA ZFAS1 in various carcinomas

Ren¹,

Zhi²,

Shen³

et al. 2017

Oncotarget

View full text Add to dashboard Cite

show abstract

Long non-coding RNA chromogenic in situ hybridisation signal pattern correlation with breast tumour pathology

Abstract: These data corroborate the involvement of three lncRNAs (HOTAIR, H19 and KCNQ1OT1) in breast tumourigenesis and support lncRNA CISH as a potential clinical assay. Importantly, CISH allows identification of the tissue compartment expressing lncRNA.

Cited by 70 publications

References 18 publications

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR

MALAT1 Long Non-coding RNA Expression in Thyroid Tissues: Analysis by In Situ Hybridization and Real-Time PCR

ZFAS1: a novel tumor-related long non-coding RNA

Prognostic and clinicopathological role of long non-coding RNA ZFAS1 in various carcinomas

Contact Info

Product

Resources

About